As per the terms of the agreement, Shionogi is responsible to pay technology access fees and payments to Shionogi for follow-up chemistry for the generation of various, novel small molecule hits against a key drug target.
Graffinity Pharma chief business officer Mathias Woker said they are pleased that Shionogi has chosen to collaborate with them to apply their fragment based screening platform to one of Shionogi’s priority discovery programs.
"Our proprietary assay/label-free SPR primary screen of 24,000 fragments and 87,000 leadlike molecules is often crucial in addressing drug targets that are difficult to screen with other technologies," Woker said.